Tagged with

USA Dr Anthony Letai reflects on how a career spanning cancer biology, clinical oncology, and translational research is shaping his early priorities as Director of the National Cancer Institute. The conversation examines how NCI is navigating a shifting global research landscape while accelerating innovation, strengthening evidence-based decision-making, and reinforcing confidence across…

Taiwan Since arriving at Organon Taiwan two years ago, Robert Mitchell has focused on growing patient access, revenue, and investments while strengthening the team. Robert explains how he is prioritising government partnerships, sustainable supply chains, and women’s health innovation, while fostering an inclusive culture, digitalisation, and talent development.   We are…

Global Andrea Johnston,* Senior Phorum Director at BioPhorum,** argues that the biopharma industry’s rapid embrace of digital twins is being undermined by a fundamental problem: agreeing what a digital twin actually is. Drawing on fresh benchmarking data from leading manufacturers, Johnston contends that this lack of shared definition is slowing regulatory…

France As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site and re-centralise French operations in Lyon is more than operational streamlining; it signals a strategic recommitment to one of Europe’s…

France As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition at Lyon 1 University and endocrinologist-diabetologist at Hospices Civils de Lyon, Caussy is a leading voice in metabolic dysfunction-associated steatotic…

USA Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, reflects on the company’s journey from rescuing overlooked rare disease programs to building a growing global pharmaceutical company. He discusses Mirum’s expanding commercial portfolio, pipeline momentum, and disciplined acquisition strategy, while emphasizing the importance of patient-centered execution in rare disease. Peetz also…

USA Precision medicine increasingly depends on diagnostics that can keep pace with therapeutic innovation while remaining accessible in real-world care. Jonathan Arnold reflects on how QIAGEN approaches oncology and emerging hereditary disease programmes by aligning diagnostic development with pharmaceutical pipelines, prioritising decentralisation, and investing in technologies that support both translational insight…

Hong Kong Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute (GBAICTI), Hong Kong’s long-established academic and regulatory strengths are being connected with the scale, infrastructure, and talent of the wider…

UAE Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase trials. She discusses patient access, genomics integration, sponsor engagement, and why MENA is emerging as a credible hub for innovation…

China China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy Bi of PharmaBoardroom content partner Selesta writes, while early-stage deal volume cooled, strategic liquidity remained robust for assets with mature…

MEA For medtech companies operating in the Middle East and Africa, bringing high-tech devices to market alone is no longer enough; reliability, uptime, and lifecycle performance have become just as critical.   Leading players such as Olympus Medical Systems are differentiating themselves by investing in service capability, ensuring that engineers responsible…

France Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33 Californie, a boutique investment firm which combines capital with strategic guidance, de-risking start-ups before Series A financing. As he explains,…